Recombinant activated factor VII (rFVIIa) has been used 'off licence' to successfully treat bleeding and reduce transfusion requirements in complex cardiac surgery. However, concerns over thrombogenic side-effects have limited but not excluded its use in patients undergoing coronary artery bypass surgery (CABG).
Recombinant activated factor VII (rFVIIa) has been used 'off label' to successfully treat bleeding and reduce transfusion requirements in aortic, valvular and complex cardiac surgery [1] [2] [3] [4] . However, concerns over thrombogenic side-effects 2,5,6 have limited but not excluded its use in patients undergoing coronary artery bypass graft surgery (CABG), and in patients for non-cardiac surgery who have known coronary artery disease.
We present two cases of CABG (one 'on pump' and one 'off pump') which were complicated by intra-operative aortic dissection and severe bleeding. In both cases the bleeding was successfully treated with rFVIIa but one patient suffered signs of early graft failure while the other did not.
CASE HISTORIES Case 1
A 71-year-old man weighing 84 kg presented for urgent CABG. He was a known hypertensive who had an antero-lateral non-ST elevation myocardial infarction (NSTEMI) six weeks previously.
Preoperative medication consisted of perindopril, amlodipine, atenolol and simvastatin. Clopidogrel had been stopped for three weeks and aspirin for eight days.
Induction and maintenance of anaesthesia were uneventful. Three coronary artery bypass grafts were performed 'off pump'. After completion of the last graft aortic dissection was suspected clinically and confirmed on transoesophageal echocardiography (TOE). Heparin 300 Iu/kg and a loading dose of aprotinin were administered and cardiopulmonary bypass (CPB) commenced. Sodium thiopentone 2g and dexamethasone 20 mg were given prior to deep hypothermic circulatory arrest (DHCA) at 15°C. The ascending aorta was repaired and the vein grafts reimplanted. The patient was weaned from bypass and residual heparin neutralized with protamine sulphate 3 mg/kg. Despite a return to the baseline activated clotting time (ACT), haemostasis was difficult to achieve and the patient continued to bleed from multiple sites. Three units of packed red cells (PRC), one litre of cell save blood, four units of fresh frozen plasma (FFP) and 18 units (or three adult therapeutic units) of platelets were given and despite a normal thromboelastogram (TEG) and fibrinogen level, the bleeding continued. Therefore after consultation with the haematology department, 7.2 mg of rFVIIa (86 μg/kg) was given.
Following this, haemostasis was achieved and the patient transferred to the cardiac intensive care unit (CICu). The total operating time was nine hours.
He was extubated on the third postoperative day but suffered several episodes of ventricular tachycardia (VT) treated with intravenous amiodarone. Later the same day he had a VT cardiac arrest and was successfully resuscitated with one DC shock at 200 Joules and a lignocaine infusion was added to his treatment. Blood testing showed a troponin I rise of 26 μg/l. Transthoracic echocardiography (TTE) showed an impaired left ventricle with lateral and posterior wall hypokinesia. His episodes of VT became less frequent and he was discharged from CICu on the tenth postoperative day. He had suffered no renal or gastrointestinal complications but weakness of both arms was noted.
He was discharged from hospital 17 days after his operation but required readmission three times over the next few months for management of his cardiac failure. An implantable cardio-defibrillator (ICD) was inserted four months after his surgery.
On telephone follow-up seven months after surgery, his cardiac failure was well controlled and the main residual problem was fine motor function of his hands.
Case 2
A 73-year-old woman weighing 66 kg was admitted to the coronary care unit with a NSTEMI. Transthoracic echocardiography showed prolapse of the anterior mitral valve leaflet with moderate to severe mitral regurgitation. urgent angiography demonstrated triple vessel disease. Percutaneous catheter revascularization of the right coronary artery was unsuccessful due to ongoing chest pain and ischaemia and an intra-aortic balloon pump (IABP) was inserted. Attempts to wean the IABP were unsuccessful, so she underwent emergency CABG and mitral valve replacement. Immediate preoperative medication consisted of an isosorbide dinitrate infusion, bisoprolol, frusemide, amlodipine and omeprazole. Her aspirin and enoxaparin sodium (1 mg/kg) had been stopped the day before surgery.
Induction of anaesthesia was uneventful. Prolapse of the anterior mitral valve leaflet with severe mitral regurgitation was confirmed on TOE. The baseline ACT was 135 seconds and a loading dose of aprotinin was given. After administration of heparin 20,000 Iu the ACT was only 273 seconds, so a further 20,000 Iu was given. This increased the ACT to 330 seconds and so another 20,000 Iu of heparin was given resulting in an ACT of 374 seconds and CPB was instituted.
The mitral valve was irreparable so a mechanical valve was implanted and then three CABGs performed. Weaning from bypass was achieved using the IABP and residual heparin was neutralized with protamine sulphate 3 mg/kg. As the aortic cannula was extracted there was clear evidence of dissection, confirmed on TOE. Therefore the left femoral artery was cannulated, a further 35,000 Iu of heparin administered, CPB reinstituted, sodium thiopentone 2g and dexamethasone 10 mg given and the patient cooled to 15°C for circulatory arrest. The ascending aorta was replaced and the vein grafts reimplanted. Weaning from CPB was achieved using atrial pacing, IABP, enoximone and noradrenaline.
Residual heparin was neutralized with protamine sulphate 3 mg/kg but despite a return to the baseline ACT there was bleeding from multiple sites. Eight units of PRCs, six units of FFP and 12 units (two adult therapeutic units) of platelets were transfused and despite normothermia, a normal TEG and normal fibrinogen level, she continued to bleed. Therefore after consultation with the haematology department, 4.8 mg of rFVIIa (75 μg/kg) was administered. Satisfactory haemostasis was then achieved and the patient transferred to the CICu. The total operating time was over ten hours.
She was extubated on the second postoperative day and the IABP was removed the next day. She suffered mild, transient renal impairment but did not require dialysis (peak creatinine 243 μmol/l) and had no respiratory, gastrointestinal or neurological complications. She was discharged to the ward on the eighth postoperative day and from hospital nineteen days after her surgery.
On telephone follow-up six months later she described a good exercise tolerance with mild breathlessness on exertion.
DISCuSSION
We have described the successful use of rFVIIa in two patients with severe bleeding after CABG surgery complicated by aortic dissection. The first patient suffered from severe postoperative arrhythmias, myocardial infarction, cardiac arrest and worsening left ventricular dysfunction suggesting graft patency may have been impaired. The other patient remained symptom free with no angina at six months suggesting graft patency was unaffected by the use of rFVIIa. Although neither patient underwent angiography, we believe case 1 demonstrates that graft thrombosis remains a concern after 'off label' use of rFVIIa in CABG surgery.
Aortic dissection is a rare but recognized complication of coronary artery bypass grafting [7] [8] [9] [10] . It is more common in off pump than on pump surgery 7 and is associated with increased haemostatic complications, morbidity and mortality 10 . The use of TOE to confirm diagnosis was used in both our cases and is thought to improve outcome 8,10 by facilitating prompt surgical intervention.
Recombinant FVIIa acts by forming complexes with exposed tissue factor at the site of vascular injury. This is independent of the presence of factors VIII and IX. Administration of high dose rFVIIa results in supra-normal levels of factor VIIa causing faster and greater thrombin generation 11 . A dose of 90 μg/kg is licensed in the treatment of bleeding in patients with haemophilia with inhibitors to factors VIII or IX, congenital factor VII deficiency and Glanzmann's thrombasthenia refractory to platelet transfusion. Off label use as a 'rescue' therapy for severe haemorrhage or as a means of reducing allogenic transfusion requirements has become increasingly popular [12] [13] [14] [15] . Recombinant FVIIa can restore thrombin generation even in the presence of thrombocytopenia, platelet dysfunction, fibrinolysis or generalized coagulation factor deficiency. This makes it an ideal agent for use in cardiac surgery where bleeding is often multifactorial in origin.
The main concern using rFVIIa in cardiac surgery is thromboembolism. Although thromboses are rare in haemophiliacs because of their underlying coagulopathy, the prophylactic use of rFVIIa in surgical patients or those without coagulopathy is not without risk. One study of patients with intracerebral haemorrhage showed the incidence of arterial thromboembolic events (myocardial ischaemia and cerebral infarction) was significantly increased in the rFVIIa group compared with placebo 6 . Our first case showed evidence of cardiac ischaemia characterized by postoperative arrhythmias and worsening left ventricular dysfunction. These symptoms are suggestive of early graft thrombosis although we have no angiographic evidence to prove this. The second case showed no symptoms of ischaemia suggesting graft patency was preserved.
Positive reporting bias means that patients treated with rFVIIa who do not have any complications are much more likely to be reported than those who do. Also, as demonstrated in our first case, even if a thromboembolic event is strongly suspected it is often not proven, further adding to the publication bias.
The reason our first case may have suffered early graft thrombosis while the second case did not is unclear and makes it difficult to predict patients at risk of early graft failure. The typical dose of 90 μg/kg recommended for haemophiliacs, may be inadvisable in patients with CABG until more evidence is available concerning its effect on graft patency. Our two patients received 86 and 75 μg/kg respectively. We used these doses (7.2 mg and 4.8 mg respectively) as this corresponded to whole ampoules of rFVIIa which is prepared as 1.2 mg, 2.4 mg and 4.8 mg vials of powder for reconstitution. In the literature, off label use in various types of surgery has used doses ranging from 20 μg/kg to 160 μg/kg. In one study on cardiac surgical patients 4 , when a dose of 2.4 mg (approximately 35 μg/kg) was given, a repeat dose was needed in a third of the patients whereas a 4.8 mg dose (approximately 70 μg/kg) was uniformly effective. In cardiac surgery, Welsby has suggested it may be more appropriate to administer smaller, repeated doses (20-40 μg/kg) to reverse coagulopathy 16 . This would have the dual benefit of minimizing the risk of early graft thrombosis and reducing drug cost. However more work is needed to determine the optimal dose and risk:benefit ratio of rFVIIa in patients undergoing CABG surgery.
In summary, we have presented two cases demonstrating that rFVIIa can be used successfully to treat bleeding after CABG complicated by aortic dissection but this may be at the potential risk of early graft failure.
